Briacell Therap (NASDAQ:BCTX) Sees Significant Decline in Short Interest

Briacell Therap (NASDAQ:BCTX) was the recipient of a large decrease in short interest during the month of February. As of February 13th, there was short interest totaling 102,666 shares, a decrease of 27.8% from the January 29th total of 142,140 shares. Based on an average daily volume of 189,938 shares, the short-interest ratio is presently 0.5 days. Currently, 1.4% of the company’s stock are sold short. Currently, 1.4% of the company’s stock are sold short. Based on an average daily volume of 189,938 shares, the short-interest ratio is presently 0.5 days.

Hedge Funds Weigh In On Briacell Therap

A hedge fund recently bought a new stake in Briacell Therap stock. Flagship Harbor Advisors LLC acquired a new stake in Briacell Therap (NASDAQ:BCTX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 4,000 shares of the company’s stock, valued at approximately $28,000. Flagship Harbor Advisors LLC owned about 0.21% of Briacell Therap at the end of the most recent reporting period. 15.42% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Briacell Therap in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $320.00.

Briacell Therap Price Performance

NASDAQ BCTX opened at $3.82 on Friday. The stock’s fifty day moving average price is $5.44 and its 200 day moving average price is $8.35. Briacell Therap has a 1 year low of $3.60 and a 1 year high of $98.20. The company has a market cap of $27.70 million, a price-to-earnings ratio of -0.09 and a beta of 1.42.

Briacell Therap (NASDAQ:BCTX) last issued its quarterly earnings results on Monday, December 15th. The company reported ($4.35) EPS for the quarter, topping analysts’ consensus estimates of ($12.11) by $7.76. Research analysts expect that Briacell Therap will post -2.45 earnings per share for the current year.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.